Skip to content
zameds

Atorvastatin (Restan-atorvastatin, Adco Atorvastatin, Alcholtin)

Atorvastatin

Adcock ingram limited

Every registration of this product has been cancelled.

Registration

Applicant
Adcock ingram limited
Registrations
9

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Restan-atorvastatin 10 MG

EACH TABLET CONTAINS ATORVASTATIN 10,0 mg

10 mg43111343/7.5/1113CancelledNot determinedNone
Restan-atorvastatin 20 MG

EACH TABLET CONTAINS ATORVASTATIN 20,0 mg

20 mg43111443/7.5/1114CancelledNot determinedNone
Restan-atorvastatin 40 MG

EACH TABLET CONTAINS ATORVASTATIN 40,0 mg

40 mg43111543/7.5/1115CancelledNot determinedNone
Adco atorvastatin 10 MG

EACH TABLET CONTAINS ATORVASTATIN 10,0 mg

10 mg43111643/7.5/1116CancelledNot determinedNone
Adco atorvastatin 20 MG

EACH TABLET CONTAINS ATORVASTATIN 20,0 mg

20 mg43111743/7.5/1117CancelledNot determinedNone
Adco atorvastatin 40 MG

EACH TABLET CONTAINS ATORVASTATIN 40,0 mg

40 mg43111843/7.5/1118CancelledNot determinedNone
Alcholtin 10

EACH TABLET CONTAINS ATORVASTATIN 10,0 mg

1043111943/7.5/1119CancelledNot determinedNone
Alcholtin 20

EACH TABLET CONTAINS ATORVASTATIN 20,0 mg

2043112043/7.5/1120CancelledNot determinedNone
Alcholtin 40

EACH TABLET CONTAINS ATORVASTATIN 40,0 mg

4043112143/7.5/1121CancelledNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Atorvastatin

    Consolidated Schedules 06 July 2026, line 5376

  • S4: Ezetimibe

    Consolidated Schedules 06 July 2026, line 6302

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C33H35FN2O5558.60 g/mol

(3R,5R)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid

Drag to rotate. Structure from PubChem CID 60823.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles